Wikidata

(Q64139367)

English

A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site

clinical trial

In more languages

Statements

short name
CUPISCO (English)
0 references
title
A Phase II, Randomized, Active-Controlled, Multi-Center Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Guided by Genomic Profiling Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site Who Have Received Three Cycles of Platinum Doublet Chemotherapy (English)
0 references
sponsor
Hoffmann-La Roche
0 references
country
Australia
0 references
Austria
0 references
Brazil
0 references
Bulgaria
0 references
Croatia
0 references
Estonia
0 references
Finland
0 references
France
0 references
Germany
0 references
Greece
0 references
Hungary
0 references
Republic of Ireland
0 references
Israel
0 references
Italy
0 references
Latvia
0 references
Norway
0 references
Poland
0 references
Portugal
0 references
Romania
0 references
Spain
0 references
Switzerland
0 references
Turkey
0 references
United Kingdom
0 references
start time
10 July 2018
0 references
end time
25 June 2021
0 references
number of participants
790
0 references
research intervention
paclitaxel
0 references
cisplatin
0 references
bevacizumab
0 references
carboplatin
0 references
pertuzumab
0 references
vemurafenib
0 references
minimum age
18 year
0 references

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    Retrieved from "https://www.wikidata.org/w/index.php?title=Q64139367&oldid=2093771451"